论文部分内容阅读
目的探讨替米沙坦与苯磺酸氨氯地平联用及单用苯磺酸氨氯地平对高血压合并2型糖尿病患者血脂及血糖的影响。方法选取2013年4月至2014年4月辽宁省普兰店市中心医院收治的高血压合并糖尿病患者112例为研究对象,按随机数字表法分为观察组和对照组,每组56例。观察组患者给予替米沙坦(40~80 mg)联合苯磺酸氨氯地平(2.5~5.0 mg),对照组患者给予苯磺酸氨氯地平(2.5~5.0 mg),均为每天1次,早晨口服相应药物,连续观察24周,比较治疗前及治疗后两组患者血压、血脂、血糖及体重指数变化,记录不良反应。结果治疗24周后,观察组患者三酰甘油、空腹血糖较治疗前显著降低(P<0.05),与对照组治疗后比较,差异有统计学意义(P<0.05);观察组治疗后低密度脂蛋白胆固醇较治疗前明显降低(P<0.05),与对照组治疗后比较差异无统计学意义(P>0.05)。结论替米沙坦与苯磺酸氨氯地平联用对高血压合并2型糖尿病患者既能很好地控制血压,又能显著改善患者的血脂、血糖。
Objective To investigate the effects of telmisartan combined with amlodipine besylate and amlodipine besylate on blood lipids and blood glucose in type 2 diabetes mellitus patients with hypertension. Methods From April 2013 to April 2014, 112 patients with hypertension and diabetes mellitus in Pulandian Central Hospital of Liaoning Province were selected as the research object. According to the random number table, the patients were divided into observation group and control group, with 56 cases in each group. Patients in the observation group were treated with telmisartan (40-80 mg) and amlodipine besylate (2.5-5.0 mg), and patients in the control group were treated with amlodipine besylate (2.5-5.0 mg) once daily Oral administration of the corresponding drugs in the morning, continuous observation for 24 weeks, comparing the two groups before and after treatment, blood pressure, blood lipids, blood glucose and body mass index changes recorded adverse reactions. Results After treatment for 24 weeks, the triglyceride and fasting blood glucose in observation group were significantly lower than those before treatment (P <0.05), and the difference was statistically significant (P <0.05) Lipoprotein cholesterol was significantly lower than that before treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusion Telmisartan combined with amlodipine besylate can both control blood pressure and improve blood lipid and blood sugar in patients with type 2 diabetes mellitus and hypertension.